Dupixent  Linked to Rare T-Cell Lymphoma 

Dupixent (dupilumab) has been a “blockbuster” drug for millions suffering from severe eczema (atopic dermatitis), asthma, and nasal polyps. However, recent medical studies and a growing number of federal lawsuits have raised  serious concerns about a potential link between Dupixent and a rare form of blood cancer known as Cutaneous T-Cell Lymphoma (CTCL).

At TheLawFirm.com, we are fighting for justice for patients potentially affected by this drug, and to ensure patients are informed about  the emerging evidence regarding “masking” and “acceleration” of this aggressive cancer.

What is “Masking”?

One of the most dangerous aspects of the current Dupixent controversy is that Cutaneous T-Cell Lymphoma (CTCL) often presents as red, scaly, itchy patches on the skin, which are virtually the same symptoms  as the severe eczema Dupixent is prescribed to treat.

Lawsuits filed in 2025 and 2026 allege that:

• Symptom Masking: Dupixent may suppress the outward inflammation of the skin, making the cancer appear to “clear up” while it continues to progress internally.
• Delayed Diagnosis: Because manufacturers allegedly failed to warn doctors to biopsy persistent rashes before or during treatment, many patients did not receive a cancer diagnosis until it had reached an advanced, life-threatening stage.
• Disease Acceleration: Some studies suggest the drug’s impact on the immune system may actually accelerate the growth of pre-existing, undiagnosed T-Cell malignancies.

Key Evidence & Medical Studies

The momentum behind these lawsuits stems from several peer-reviewed studies published in 2024 and 2025:

• The JAAD Study (2024): Research published in the Journal of the American Academy of Dermatology found that patients treated with Dupixent were 4.1 times more likely to be diagnosed with CTCL than those who were not.
• Risk Escalation: Data indicate that for patients who remain on the drug for at least 16 weeks, the risk for certain T-Cell and NK-cell lymphomas could increase even further.

FDA Safety Signal: In March 2025, the FDA officially placed Dupixent on its safety signal list to investigate reports of T-Cell lymphoma submitted through the Adverse Event Reporting System (FAERS).Litigation Status

As of March 2026, the  attorneys for Plaintiffs affected by Dupixent are working to consolidate the litigation  from individual filings to a coordinated national effort.

• Motion to Consolidate: In February 2026, a motion was filed with the Judicial Panel on Multidistrict Litigation (JPML) to centralize all federal Dupixent lawsuits into a single Multidistrict Litigation (MDL).
• Primary Venue: Attorneys have requested that these cases be handled in the Northern District of Georgia, which currently hosts the highest volume of filed claims.
• The Allegation: The core of the litigation remains a “failure to warn” claim. Plaintiffs argue that Sanofi and Regeneron knew about the lymphoma risks but prioritized the drug’s $20 billion annual revenue over patient safety.

Do You Qualify for a Claim?

Our legal team is  currently screening individuals who meet specific criteria. . You may be eligible to participate in this litigation if:

1. Documented Use: You were prescribed and used Dupixent (injections) for at least three to six months.
2. Cancer Diagnosis: You were later diagnosed with a form of T-Cell Lymphoma, such as:
   • Cutaneous T-Cell Lymphoma (CTCL)
   • Mycosis Fungoides
   • Sézary Syndrome
3. No Prior History: You had no history of lymphoma or skin cancer prior to starting Dupixent treatment.

Warning Signs to Discuss With Your Doctor

If you are currently taking Dupixent, do not stop without consulting your physician. However, be vigilant for “red flags” that persist despite treatment:

• Raised, leathery skin patches that feel different from typical eczema.
• Swollen lymph nodes in the neck, armpits, or groin.
• Unexplained fatigue, night sweats, or weight loss.